# An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3

> **NCT05815004** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **AVROBIO**

## Conditions studied

- Gaucher Disease, Type 3

## Interventions

- **DRUG:** Gene therapy
- **DRUG:** Enzyme Replacement Agent

## Key facts

- **NCT ID:** NCT05815004
- **Lead sponsor:** AVROBIO
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-10
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Further development of programs halted
- **Last updated:** 2023-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05815004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05815004, "An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05815004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*